Trial Profile

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 01 Mar 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ragifilimab (Primary)
Indications Adenocarcinoma; Endometrial cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
Focus Adverse reactions; First in man; Proof of concept
Sponsors Incyte Corporation

Most Recent Events

13 Apr 2020 Status changed from active, no longer recruiting to completed.
12 Jun 2019 Planned End Date changed from 1 Aug 2019 to 1 Mar 2020.
12 Jun 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Mar 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com